Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: A single-center experience

Transfusion Medicine and Hemotherapy

Volumn 37, Issue 1, 2010, Pages 13-19

  Edel, Elvira ^a   Al Ali, Haifa Kathrin ^a   Seeger, Susanne ^b   Kauschat, Dörte ^b,c   Matthes, Gert ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b Octapharma GmbH   (Germany)

^c Sanofi   (Germany)

Author keywords

ADAMTS 13; SDP; Solvent detergent treated plasma; Therapeutic plasma exchange; Thrombotic thrombocytopenic purpura; TPE; TTP

Indexed keywords

ACETYLSALICYLIC ACID; DEFIBROTIDE; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; PLASMA SUBSTITUTE; RITUXIMAB; SOLVENT DETERGENT PLASMA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMOLYTIC ANEMIA; HUMAN; MALE; PATIENT SAFETY; PLASMAPHERESIS; RECURRENT DISEASE; REMISSION; THERAPY EFFECT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 77149138606     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000264996     Document Type: Article

References (57)

1. Moschcowitz E: Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc N Y Soc 2006;24:21-24.
2. Allford SL, Hunt BJ, Rose P, Machin SJ: Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556-573.
3. Rock G, Kelton JG, Shumak KH, Buskard NA, Sutton DM, Benny WB: Laboratory abnormalities in thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Br J Haematol 1998;103: 1031-1036.
4. Moake JL, Byrnes JJ, Troll JH, Rudy CK, Hong SL, Weinstein MJ, Colannino NM: Effects of freshfrozen plasma and its cryosupernatant fraction on von Willebrand factor multimeric forms in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1985;65:1232-1236.
5. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA: ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033-4039.
6. Handin RI, Wagner DD: Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb 1989;9:233-259.
7. Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339: 1585-1594.
8. Furlan M, Robles R, Solenthaler M, Lammle B: Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998;91:2839-2846.
9. Tsai HM, Li A, Rock G: Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001;47:387-392.
10. Torok TJ, Holman RC, Chorba TL: Increasing mortality from thrombotic thrombocytopenic purpura in the United States - analysis of national mortality data, 1968-1991. Am J Hematol 1995;50: 84-90.
11. Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, Walker AM: Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology 2004;15:208-215.
12. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393-397.
13. Fontana S, Kremer Hovinga JA, Lammle B, Mansouri TB: Treatment of thrombotic thrombocytopenic purpura. Vox Sang 2006;90:245-254.
14. Mokrzycki MH, Kaplan AA: Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994;23:817-827.
15. Zeitler H, Ulrich-Merzenich G, Walger P, Bartels M, Goldmann G, Vetter H, Oldenburg J: Treatment of adults with clinically suspected severe thrombotic thrombocytopenic purpura - experiences of a single centre. Transfus Med Hemother 2007;34:64-72.
16. Rizvi MA, Vesely SK, George JN, Chandler L, Duvall D, Smith JW, Gilcher RO: Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000;40:896-901.
17. Muncunill J: Thrombotic thrombocytopenic purpura (TTP): is any plasma useful to treat the TTP? ISBT Science Series 2007;2:233-239.
18. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago BP, Horowitz M, Pehta J: Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994;84:490-497.
19. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ: Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:756-758.
20. Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F: Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 2002;91:1056-1059.
21. McCarthy LJ, Dlott JS, Orazi A, Waxman D, Miraglia CC, Danielson CF: Thrombotic thrombocytopenic purpura: yesterday, today, tomorrow. Ther Apher Dial 2004;8:80-86.
22. Edel E, Matthes G: Treatment of thrombotic thrombocytopenic purpura (TTP) by plasma exchange. Platelets 2004;15:479-517.
23. Scully M, Longair I, Flynn M, Berryman J, Machin SJ: Cryosupernatant and solvent detergent freshfrozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007;93:154-158.
24. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N: Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. J Clin Apher 2001;16:134-138.
25. Bux J: Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 2005;89:1-10.
26. Silliman CC, Ambruso DR, Boshkov LK: Transfusion-related acute lung injury (TRALI). Blood 2005;105:2266-2273.
27. Stainsby D, Jones H, Milkins C, Gibson B, Norfolk DR, Revill J, Atterbury CLJ: SHOT - Serious hazards of transfusion. Annual Report 2003. www. shotuk.org/.
28. Flesland O, Seghatchian J, Solheim BG: The Norwegian Plasma Fractionation Project - a 12 year clinical and economic success story. Transfus Apher Sci 2003;28:93-100.
29. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, Santiago-Borrero P, Horowitz M, Pehta J: Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994;84:490-497.
30. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ: Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Br J Haematol 1996;94:756-758.
31. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E,Hassenpflug WA, Harberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel DE, Obser T, Santer R, Sykora K-W: Von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845-1850.
32. Zeigler ZR, Shadduck RK, Gryn JF, Rintels PB, George JN, Besa EC, Bodensteiner D, Silver B, Kramer RE: Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001;16:19-22.
33. Altuntas F, Aydogdu I, Kabukcu S, Kocyigit I, Cikim K, Sari I, Erkut MA, Eser B, Ozturk A, Kaya E, Cetin M, Keskin A, Unal A: Therapeutic plasma exchange for the treatment of thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci 2007;36:57-67.
34. Rock G, Anderson D, Clark W, LeBlond P, Palmer D, Sternbach M, Sutton D, Wells G: Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005;129:79-86.
35. Heger A, Kannicht C, Römisch J, Svae TE: Normal levels of ADAMTS 13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 2007; 92:206-212.
36. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ: Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004;14:39-44.
37. Rock G, Yousef H, Neurath D, Lu M: ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma. Transfus Apher Sci 2006;35:235-238.
38. Evans G, Llewelyn C, Luddington R, Baglin TP, Williamson LM: Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999;21:119-123.
39. Allford SL, Harrison P, Lawrie A, Mackie IJ, Machin SJ: The role of solvent-detergent treated plasma (Octaplas) in acute thrombotic thrombocytopenic purpura. Vox Sang 2000;78(suppl 1):abstract 0043.
40. Stanworth SJ, Hyde CJ, Murphy MF: Evidence for indications of fresh frozen plasma. Transfus Clin Biol 2007;14:551-556.
41. Flesland O, Jorgensen J, Krusius T, Säfwen J, Gudmundson S: Haemovigilance in the Nordic countries. Haematologica 2005;90:135.
42. Hofer C, Genser D, Priebe B, Steif S: Hämovigilanz-Jahresbericht 2005. 2006:1-42. www.goeg.at/media/ download/berichte/HaemJB-2005-Endbericht. pdf.
43. Genser D, Hofer C, Steif S: Hämovigilanz-Jahresbericht 2003. 2004. www.goeg.at/media/download/ berichte/HaemJB-2003.pdf.
44. Hofer C, Genser D, Steif S: Hämovigilanz-Jahresbericht 2004. 2005. www.goeg.at/media/download/ berichte/HaemJB-2004.pdf.
45. Priebe B, Hofer C, Genser D, Gollmer A: Hämovigilanz-Jahresbericht 2006. 2007. www.goeg.at/ media/download/berichte/Haemovigilanz-Jahresbericht- 2006.pdf.
46. Brunskill SJ, Tusold A, Benjamin S, Stanworth SJ, Murphy MF: A systematic review of randomized controlled trials for plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Transfus Med 2007;17:17-35.
47. Barz D: Detection of antigen structures in blood cells in various prepared plasma transfusions. Anaesthesiol Reanim 1994;19:155-158.
48. Lefevre H, Walther-Wenke G, Burkhard J: Leukozytendepletion. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 1999;42:121-131.
49. Barz D, Kentouche K, Zintl F, Göhler T, Budde U: Treatment with solvent detergent (SD) treated plasma is efficacious and well tolerated in thrombotic thrombo-cytopenic purpura (TTP) due to congenital von Willebrand factor-cleaving protease (VWF-DP)-deficiency. Vox Sang 2002;83:99.
50. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ: Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 2003;121:778-785.
51. Beeck H, Hellstern P: In vitro characterization of solvent/detergent- treated human plasma and of quarantine fresh frozen plasma. Vox Sang 1998;74: 219-223.
52. Hellstern P: Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 2004;11:346-350.
53. Hellstern P, Haubelt H: Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy. Thromb Res 2002;107(suppl 1):S3-S8.
54. Kreil TR, Berting A, Kistner O, Kindermann J: West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003;43:1023-1028.
55. Rock G, Clark B, Sutton D: The Canadian Apheresis Registry. Transfus Apher Sci 2003;29:167-177.
56. Popovsky MA: Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang 2004; 87:62-65.
57. Sachs UJ, Kauschat D, Bein G: White blood cellreactive antibodies are undetectable in solvent/detergent plasma. Transfusion 2005;45:1628-1631.